Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 24;592(7854):463–468. doi: 10.1038/s41586-021-03363-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a, b, Semi-quantitative analysis of T cell (a) and B cell (b) immune responses (IR) in all patients in the IDS measured by IFNγ enzyme-linked immunosorbent spot (ELISpot) assay (a) or IDH1 peptide enzyme-linked immunosorbent assay (ELISA) (b) (n = 30 patients). Patients are classified as T cell responders (n = 24 patients) and non-responders (n = 6 patients) on the basis of specific spot count cut-off of 50 as defined in the study protocol. Response for each visit (V) is shown. c, Flow cytometric effector phenotyping of peripheral IDH1-vac-induced T cells (single live CD3⁺ cells) from available patient samples with high MSS (n = 5 patient samples). Relative values after re-stimulation with IDH1(R132H) peptide compared to negative control peptide (myelin oligodendrocyte glycoprotein; MOG) are shown. FC, fold-change. Gating strategy is shown in Extended Data Fig. 4c. d, Correlation of intratumoral IDH1(R132H) peptide presentation at baseline (quantified by PLA signal) with the magnitude and sustainability of specific peripheral T cell responses (quantified by the MSS; see Extended Data Fig. 5). r, Pearson correlation coefficient. Patient ID numbers are shown in a–d.